Welcome to the Allergy Therapeutics Investor Relations Centre.

"We continue to execute our strategy to create significant value for our shareholders."

Manuel Llobet - CEO
Interim Results 2020 Webcast link

UK dial-in: +44 (0) 2071 928000 / US dial-in: +16315107495 / Conference ID: 3622619

Annual Report 2019

This year’s performance has shown yet again that Allergy Therapeutics’ focus on scientifically advanced products that are convenient for patients is the right approach for our business.

AT AR19 Cover 169x239.jpg